SE0301372D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- SE0301372D0 SE0301372D0 SE0301372A SE0301372A SE0301372D0 SE 0301372 D0 SE0301372 D0 SE 0301372D0 SE 0301372 A SE0301372 A SE 0301372A SE 0301372 A SE0301372 A SE 0301372A SE 0301372 D0 SE0301372 D0 SE 0301372D0
- Authority
- SE
- Sweden
- Prior art keywords
- novel compounds
- methods
- pharmaceutical compositions
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0301372A SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Novel compounds |
EP04731527A EP1625127B1 (en) | 2003-05-09 | 2004-05-06 | Azaindole compounds as kinase inhibitors |
AU2004236146A AU2004236146B2 (en) | 2003-05-09 | 2004-05-06 | Azaindole compounds as kinase inhibitors |
US10/556,227 US20060287354A1 (en) | 2003-05-09 | 2004-05-06 | Azaindole compounds as kinase inhibitors |
DE602004006618T DE602004006618T2 (de) | 2003-05-09 | 2004-05-06 | Azaindolverbindungen als kinaseinhibitoren |
ES04731527T ES2286634T3 (es) | 2003-05-09 | 2004-05-06 | Compuestos de azaindol como inhibidores de quinasas. |
CNA2004800126269A CN1784403A (zh) | 2003-05-09 | 2004-05-06 | 作为激酶抑制剂的吖吲哚化合物 |
MXPA05012026A MXPA05012026A (es) | 2003-05-09 | 2004-05-06 | Compuestos de azaindol como inhibidores de cinasa. |
AT04731527T ATE362932T1 (de) | 2003-05-09 | 2004-05-06 | Azaindolverbindungen als kinaseinhibitoren |
JP2006508046A JP2006525998A (ja) | 2003-05-09 | 2004-05-06 | キナーゼ阻害剤としてのアザインドール化合物 |
BRPI0410117-0A BRPI0410117A (pt) | 2003-05-09 | 2004-05-06 | composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto |
PCT/SE2004/000696 WO2004099205A1 (en) | 2003-05-09 | 2004-05-06 | Azaindole compounds as kinase inhibitors |
CA002523922A CA2523922A1 (en) | 2003-05-09 | 2004-05-06 | Azaindole compounds as kinase inhibitors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0301372A SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0301372D0 true SE0301372D0 (sv) | 2003-05-09 |
Family
ID=20291270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0301372A SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Novel compounds |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060287354A1 (pt) |
EP (1) | EP1625127B1 (pt) |
JP (1) | JP2006525998A (pt) |
CN (1) | CN1784403A (pt) |
AT (1) | ATE362932T1 (pt) |
AU (1) | AU2004236146B2 (pt) |
BR (1) | BRPI0410117A (pt) |
CA (1) | CA2523922A1 (pt) |
DE (1) | DE602004006618T2 (pt) |
ES (1) | ES2286634T3 (pt) |
MX (1) | MXPA05012026A (pt) |
SE (1) | SE0301372D0 (pt) |
WO (1) | WO2004099205A1 (pt) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
WO2006114180A1 (de) | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
AU2006251623A1 (en) * | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
ES2612196T3 (es) * | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
JP2009523812A (ja) * | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
WO2007118041A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
JP5030114B2 (ja) | 2006-09-25 | 2012-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体をモジュレートする化合物 |
WO2008079965A1 (en) | 2006-12-22 | 2008-07-03 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
KR20090106604A (ko) * | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 피리딘 화합물 |
CN101679251B (zh) | 2007-04-11 | 2013-10-02 | 橘生药品工业株式会社 | (氮杂)吲哚衍生物及其医药用途 |
EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP2217565B1 (en) | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
BRPI0820544A2 (pt) | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
KR20120108042A (ko) | 2008-03-11 | 2012-10-04 | 인사이트 코포레이션 | Jak 억제제로서의 아제티딘 및 시클로부탄 유도체 |
EP2274288A2 (en) | 2008-04-24 | 2011-01-19 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2010005782A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
JP5453437B2 (ja) | 2008-09-25 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するスルホニル化合物 |
US20110230467A1 (en) * | 2008-11-21 | 2011-09-22 | Astellas Pharma Inc. | 4,6-diaminonicotinamide compound |
WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
US8592415B2 (en) | 2009-02-11 | 2013-11-26 | Reaction Biology Corp. | Selective kinase inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為jak抑制劑之3-〔4-(7h-吡咯并〔2,3-d〕嘧啶-4-基)-1h-吡唑-1-基〕辛烷或庚腈 |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体 |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
JP5690823B2 (ja) | 2009-07-08 | 2015-03-25 | レオ ファーマ アクティーゼルスカブ | Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物 |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2486041B1 (en) | 2009-10-09 | 2013-08-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
KR102354472B1 (ko) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
CA2823935A1 (en) | 2011-01-07 | 2012-07-12 | Leo Pharma A/S | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
CA2827673C (en) | 2011-02-18 | 2020-10-27 | Novartis Pharma Ag | Mtor/jak inhibitor combination therapy |
US9115133B2 (en) | 2011-03-22 | 2015-08-25 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
JP5876146B2 (ja) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体 |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドAdvinus Therapeutics Limited | 置換された縮合三環式化合物、組成物およびその医薬用途 |
HUE055894T2 (hu) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | A ruxolitinib nyújtott felszabadulású dózisformái |
PE20151902A1 (es) | 2013-03-06 | 2015-12-26 | Incyte Corp | Proceso e intermedios para hacer un inhibidor de jak |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
KR101548492B1 (ko) | 2013-09-23 | 2015-09-01 | 건국대학교 산학협력단 | 야누스 키나아제 1 (Janus kinase 1)의 활성을 선택적으로 저해하는 4-아미노-7-아자인돌-5-카르복사마이드 유도체 |
SG11201605072VA (en) * | 2014-02-04 | 2016-08-30 | Taiho Pharmaceutical Co Ltd | Azaindole derivative |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
WO2016047678A1 (ja) * | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
WO2017091681A1 (en) | 2015-11-24 | 2017-06-01 | Aclaris Therapeutics, Inc. | Selective kinase inhibitors |
CN107513067A (zh) | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
US10316038B2 (en) | 2017-01-25 | 2019-06-11 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer |
US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIMIDINE JAK INHIBITORS AND METHODS FOR THEIR MANUFACTURE AND USE |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
DK3746429T3 (da) | 2018-01-30 | 2022-05-02 | Incyte Corp | Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on) |
IL277538B1 (en) | 2018-03-30 | 2024-05-01 | Incyte Corp | Use of JAK inhibitors to treat hidradenitis suppurativa |
CN112823005A (zh) | 2018-08-10 | 2021-05-18 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
KR20210106506A (ko) | 2018-12-21 | 2021-08-30 | 셀진 코포레이션 | Ripk2의 티에노피리딘 억제제 |
US20220185816A1 (en) * | 2019-03-14 | 2022-06-16 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
EP3962897A4 (en) | 2019-05-02 | 2022-12-14 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS |
MX2022006176A (es) | 2019-11-22 | 2022-08-17 | Incyte Corp | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2687402B1 (fr) * | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
US5389509A (en) * | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
US6686374B1 (en) * | 1999-08-12 | 2004-02-03 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
CA2699568C (en) * | 1999-12-24 | 2013-03-12 | Aventis Pharma Limited | Azaindoles |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-05-09 SE SE0301372A patent/SE0301372D0/xx unknown
-
2004
- 2004-05-06 BR BRPI0410117-0A patent/BRPI0410117A/pt not_active IP Right Cessation
- 2004-05-06 AU AU2004236146A patent/AU2004236146B2/en not_active Ceased
- 2004-05-06 ES ES04731527T patent/ES2286634T3/es not_active Expired - Lifetime
- 2004-05-06 EP EP04731527A patent/EP1625127B1/en not_active Expired - Lifetime
- 2004-05-06 DE DE602004006618T patent/DE602004006618T2/de not_active Expired - Fee Related
- 2004-05-06 US US10/556,227 patent/US20060287354A1/en not_active Abandoned
- 2004-05-06 AT AT04731527T patent/ATE362932T1/de not_active IP Right Cessation
- 2004-05-06 JP JP2006508046A patent/JP2006525998A/ja active Pending
- 2004-05-06 CN CNA2004800126269A patent/CN1784403A/zh active Pending
- 2004-05-06 WO PCT/SE2004/000696 patent/WO2004099205A1/en active IP Right Grant
- 2004-05-06 CA CA002523922A patent/CA2523922A1/en not_active Abandoned
- 2004-05-06 MX MXPA05012026A patent/MXPA05012026A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
ATE362932T1 (de) | 2007-06-15 |
WO2004099205A1 (en) | 2004-11-18 |
AU2004236146B2 (en) | 2007-12-13 |
MXPA05012026A (es) | 2006-02-03 |
US20060287354A1 (en) | 2006-12-21 |
DE602004006618T2 (de) | 2008-01-31 |
BRPI0410117A (pt) | 2006-05-23 |
EP1625127A1 (en) | 2006-02-15 |
ES2286634T3 (es) | 2007-12-01 |
JP2006525998A (ja) | 2006-11-16 |
EP1625127B1 (en) | 2007-05-23 |
AU2004236146A1 (en) | 2004-11-18 |
DE602004006618D1 (de) | 2007-07-05 |
CA2523922A1 (en) | 2004-11-18 |
CN1784403A (zh) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0301372D0 (sv) | Novel compounds | |
SE0101675D0 (sv) | Novel composition | |
SE0301373D0 (sv) | Novel compounds | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
EA200970156A1 (ru) | Пиридизиноновые производные | |
CY1109006T1 (el) | Παραγωγα πουρινης ως αναστολεις κινασης | |
EA200800546A1 (ru) | Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk) | |
HRP20070043A2 (en) | Antiviral compounds | |
EA200700188A1 (ru) | Производные замещенного 2-алкилхиназолинона как ингибиторы parp | |
CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
EA200700168A1 (ru) | Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
NO20092611L (no) | Krystallinsk faststoff Rasagilin base | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
SE0400284D0 (sv) | Novel compounds | |
EA200800393A1 (ru) | Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат | |
NO20063293L (no) | Farmasoytiske forbindelser | |
EA200701180A1 (ru) | Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств | |
UA92047C2 (uk) | Карбоніламінопіролпіразоли - потужні інгібітори кінази | |
RS20050811A (en) | Imidazopyridine intermediates | |
CY1115106T1 (el) | Ενωσεις πυρρολο[2,3-d]πυριμιδινης |